A first-in-human, phase 1/2, open-label, multi-center, dose-escalation and dose-expansion study to evaluate safety, tolerability, pharmacokinetics, and anti-tumor activity of the ATR inhibitor IMP9064 monotherapy and in combination with PARP inhibitor senaparib in patients with advanced solid tumors
Mechanism of Action
IMP9064 is designed to inhibit the function of ATR, a component of the DNA damage repair system in all cells. Inhibition of DNA damage repair interferes with the replication of rapidly dividing cells.
Senaparib (IMP4297) is an inhibitor of PARP 1 and PARP 2, both components of the DNA damage repair system.
Purpose
- How much IMP9064 can be given, alone and in combination with Senaparib, with an acceptable level of side effects
- The effects of the IMP9064 when given alone and in combination with Senaparib (good and bad)
- How much of the studies are absorbed into the blood and how fast they are removed
- If research tests can be used in the future to predict who will benefit from the study drugs
Location
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.